Roche
study shows Gazyva offers strong benefits as lymphoma drug
Send a link to a friend
[February 04, 2015]
ZURICH (Reuters) - Swiss drugmaker
Roche said on Wednesday a late-stage study involving non-Hodgkin's
lymphoma patients showed they lived longer without the disease worsening
when treated with its Gazyva drug, giving a boost to its line-up of
cancer treatments.
|
Gazyva - marketed as Gazyvaro in the European Union and Switzerland
- is being positioned as an alternative follow-on medicine to
Roche's Rituxan, or MabThera, which generated 6.9 billion Swiss
francs ($7.46 billion) in sales last year.
Roche is hoping to switch as many patients as possible to the newer
product before Rituxan faces competition from cheaper copies when
its patent protection expires.
The study showed that patients with relapsed slow-growing, or
indolent non-Hodgkin's lymphoma lived significantly longer without
their disease worsening when treated with Gazyva and bendamustine
followed by Gazyva alone, the company said in a statement.
The news was welcomed by investors, with Roche shares rising by 2.7
percent by 1057 GMT, outpacing the European healthcare sector index
which was up 0.7 percent.
"It suggests Gazyva works in a Rituxan refractory (relapsed)
population that offers sales potential in the $500 million to $1
billion range," analysts at Deutsche Bank, which has a "buy" rating
on the stock, wrote in a note.
Data from the study will be submitted to the U.S. Food and Drug
Administration, European Medicines Agency and other health
authorities for consideration for approval, the company said.
[to top of second column] |
The performance of Gazyva against Rituxan in two ongoing
head-to-head late-stage trials will be another important indicator,
analysts said.
The trials involve patients with large B-cell lymphoma and indolent
non-Hodgkin's lymphoma.
(Reporting by Joshua Franklin; Editing by Anand Basu and John
Stonestreet)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
|